Market Currents
Gilead Sciences (GILD +8.3%) says it plans to partner with Mylan (MYL -1.5%), Ranbaxy...
-
Thursday, August 2, 2012, 11:13 AM ETGilead Sciences (GILD +8.3%) says it plans to partner with Mylan (MYL -1.5%), Ranbaxy Laboratories (RBXZF.PK) and Strides Arcolab to promote access to generic versions of Gilead's HIV medicine containing Emtricitabine in developing countries. The drug is marketed by GILD under the brand names Emtriva and Truvada. WHO guidelines recommend the drug as preferred components of first and second line HIV therapy.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
